Panel. Medical R&D in microgravity: the business case @WithTheEconomist
Panel. Medical R&D in microgravity: the business case @WithTheEconomist
Uploaded May 2026 | Updated September 2026, 1 hour ago
Supported by Portuguese Space Agency

For scientists studying human health, microgravity offers a unique environment for R&D `in protein crystallisation, biomanufacturing and regenerative medicine. Which experiments offer commercial advantage? Are there already credible business cases, or are the applications still speculative? What must change for space-based R&D to deliver products, not just publications?

Moderated by: Oliver Morton, The Economist
Toby Call, Mass Balance
Avantika Gupta, Type One Ventures
Hugo André Costa, Portuguese Space Agency
Panel. Medical R&D in microgravity: the business casePanel. When to invest, pause or pull the plug?Fireside chat. Can growth be maintained when the AI novelty wears off?Panel. Future-proof or flawed? Bridging the gap between Gen Z passion and commercial capabilityPanel. Gene editing in agriculture: implications for farming and foodPanel. Building resilience into procurement decisions: how to educate your workforceAI Compute 2026 l Case study Who will control the infrastructure of intelligenceØrsted at The Economist Sustainability Week1025 Panel The superposition of utility and hype1000 Panel It takes a qubit village1620 Panel Spin-outs and superclustersWorld Cancer Series - Panel: Enhancing uptake of innovation for better outcomes
Economist Enterprise – Events |

Panel. Medical R&D in microgravity: the business case

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER